BioCardia earnings release, May 15, 2026
BioCardia Reports First Quarter 2026 Business Highlights and Financial Results
Sunnyvale, Calif. – May 15, 2026 -
BioCardia, Inc.
[Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reported financial results for the first quarter 2026 and filed its quarterly report on Form 10-Q for the three months ended March 31, 2026 with the Securities and Exchange Commission. The Company will also hold a conference call at 4:30 PM ET today in which it will discuss business highlights. Following management’s formal remarks, there will be a question-and-answer session.
Recent Business Highlights
CardiAMP® autologous cell therapy in ischemic heart failure of reduced ejection fraction (BCDA-01)
CardiAMP autologous cell therapy in chronic myocardial ischemic with refractory angina (BCDA-02)
Helix™ Biotherapeutic Delivery System
Intellectual Property
The Company’s intellectual property portfolio is robust, with more than 60 patents and patent applications worldwide.
In March, the Company announced that the Japan Patent, “Target Site Selection, Entry, and Update with Automatic Remote Image Annotation.” This patent adds further protection to BioCardia’s proprietary Heart3D™ Fusion Imaging (Heart3D) software intended for treatment planning and real-time navigation during CardiAMP Cell Therapy procedures. The allowed Japanese patent has claims on the use of Heart3D fusion imaging configured for transposing a preoperative three-dimensional image obtained by Computer Tomography (CT) or Magnetic Resonance Imaging (MRI) of the patient’s heart onto two orthogonal two-dimensional images to generate a combined three-dimensional model reconstruction of the heart on a display within or adjacent to a sterile field for navigating delivery systems and recording procedural locations.
“It has been a tremendous quarter, and we are thankful for the extensive interactions with PMDA and FDA in reviewing the CardiAMP HF clinical trial data and for their continued support. CardiAMP Cell Therapy for the treatment of ischemic heart failure is now advancing towards an expected initial regulatory approval in Japan, where cardiologists would be able to treat an estimated 20,000 patients annually having no treatment options.” said BioCardia CEO Peter Altman, Ph.D. “We have also secured FDA support for the ongoing confirmatory CardiAMP HF II trial and FDA guidance on market clearance of our best-in-class Helix Transendocardial Delivery System. Our work with our world class physician partners has potential to ultimately help millions of patients suffering from ischemic heart failure and chronic myocardial ischemia with few current therapeutic options.”
First Quarter 2026 Financial Results:
ANTICIPATED UPCOMING MILESTONES AND EVENTS:
Conference call access:
Participants can register for the conference by navigating to https://dpregister.com/sreg/10209272/104069d5d88. Please note that registered participants will receive their dial-in number upon registration. For those who have not registered, to listen to the call by phone, interested parties within the U.S. should call 1-833-316-0559 and international callers should call 1-412-317-5730 and ask to be connected to the BioCardia call. All callers should dial-in approximately 10 minutes prior to the scheduled start time and ask to be joined into the BioCardia call. The conference call will also be available through a live webcast, which can be accessed through the following link: https://event.choruscall.com/mediaframe/webcast.html?webcastid=Rt7kKGAp.
A webcast replay of the call will be available approximately one hour after the end of the call at the following link: https://services.choruscall.com/ccforms/replay.html. A telephonic replay of the call will be available and may be accessed by calling 1-855-669-9658 (toll free domestic/Canada) and 1-412-317-0088 (international toll) by using access code 4737992.
About BioCardia®
BioCardia, Inc., headquartered in Sunnyvale, California, is developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary disease. CardiAMP® autologous and CardiALLO
TM allogeneic cell therapies are the Company’s biotherapeutic platforms for the treatment of heart disease. These therapies are enabled by its Helix
TM biotherapeutic delivery and Morph® vascular navigation product platforms. BioCardia also acts as a biotherapeutic delivery partner supporting therapies for the treatment of heart failure, chronic myocardial ischemia, and acute myocardial infarction. The CardiAMP Cell Therapy Trial for Heart Failure has been supported financially by the Maryland Stem Cell Research Fund and the Center for Medicare and Medicaid Services. For more information visit: www.BioCardia.com.
Financial statements
Income Statement
Three Months ended March 31, — (Unaudited in thousands, except share and per share amounts)
| Three Months ended March 31, – 2026 | Three Months ended March 31, – 2025 | ||
|---|---|---|---|
| Costs and expenses: | Research and development | 1,235 | 1,530 |
| Costs and expenses: | Selling, general and administrative | 1,031 | 1,196 |
| Costs and expenses: | Total costs and expenses | 2,266 | 2,726 |
| Costs and expenses: | Operating loss | -2,266 | -2,726 |
| Other income (expense): | Total other income, net | 7 | 14 |
| Other income (expense): | Net loss | -2,259 | -2,712 |
| Other income (expense): | Net loss per share, basic and diluted | -0.21 | -0.59 |
| Other income (expense): | Weighted-average shares used in computing net loss per share, basic and diluted | 10,812,419 | 4,635,764 |
Balance Sheet
December 31, — (Unaudited in thousands, except share and per share amounts)
| March 31, – 2026(1) | December 31, – 2025(1) | ||
|---|---|---|---|
| Assets: | Cash and cash equivalents | 951 | 2,496 |
| Assets: | Other current assets | 189 | 236 |
| Assets: | Property, plant and equipment and other noncurrent assets | 572 | 681 |
| Assets: | Total assets | 1,712 | 3,413 |
| Liabilities and Stockholders’ Equity (Deficit) | Current liabilities | 2,778 | 2,432 |
| Liabilities and Stockholders’ Equity (Deficit) | Operating lease liability - noncurrent | 86 | |
| Liabilities and Stockholders’ Equity (Deficit) | Total stockholders’ equity (deficit) | -1,066 | 895 |
| Liabilities and Stockholders’ Equity (Deficit) | Total liabilities and stockholders’ equity (deficit) | 1,712 | 3,413 |
Full release
Forward Looking Statements... (truncated)d expenditures, the ability to raise the additional funding needed to continue to pursue BioCardia’s business and product development plans, the ability to enter licensing and partnering arrangements and overall market conditions. We may find it difficult to enroll patients in our clinical trials due to many factors, some of which are outside of our control. Slower than targeted enrollment could delay completion of our clinical trials and delay or prevent the development of our therapeutic candidates. These forward-looking statements are made as of the date of this press release, and BioCardia assumes no obligation to update the forward-looking statements.
We may use terms such as “believes,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should,” “approximately” or other words that convey the uncertainty of future events or outcomes to identify these forward-looking statements. Although we believe that we have a reasonable basis for each forward-looking statement contained herein, we caution you that forward-looking statements are not guarantees of future performance and that our actual results may differ materially from the forward-looking statements contained in this press release. As a result of these factors, we cannot assure you that the forward-looking statements in this press release will prove to be accurate. Additional factors that could materially affect actual results can be found in BioCardia’s Form 10-K filed with the Securities and Exchange Commission on March 24, 2026, under the caption titled “Risk Factors BioCardia expressly disclaims any intent or obligation to update these forward-looking statements, except as required by law.
BioCardia, Inc.
Condensed Consolidated Statements of Operations
(Unaudited in thousands, except share and per share amounts)
###
Media Contact:
Miranda Peto, Investor Relations
Email: mpeto@BioCardia.com
Phone: 650-226-0120
Investor Contact:
David McClung, Chief Financial Officer
Email: investors@BioCardia.com
Phone: 650-226-0120